Business Wire

CIRIUM

8.12.2021 10:02:24 CET | Business Wire | Press release

Share
Airline Passenger Capacity is Projected to Grow at 47% in 2022

Global aviation analytics firm Cirium, has released its second annual Airline Insights Review, which reveals an industry in recovery and poised for a projected 47% growth in capacity (the number of seats flown) in 2022. This steep increase indicates capacity could return to 2015 levels by the end of next year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005398/en/

Last year, the pandemic and its consequences wiped out 15 years of global passenger capacity growth—based on the total number of seats flown—in a matter of months, reducing 2020 capacity flown to levels last seen in 2005.

Although recovery was varied in 2021, global capacity is forecasted to return to capacity levels seen in 2006 by the end of the year.

Regions with strong domestic markets showed accelerated recovery this year—in particular, in the US and China. In fact, Chinese domestic flights are up 6% compared to pre-pandemic levels in 2019.

Of all the flights tracked January to October 31 worldwide, 78% were domestic flights. International flights experienced a slow recovery with many restrictions in place until Q4 of 2021, and some restrictions still in place, depending on the routes. Indeed, international flights saw a 6% growth in 2021 compared to the same period in 2020.

“The past year has had its challenges as we continued to face fluctuating cases of COVID-19, new variants—most recently Omicron—and varied vaccination programs per country. There is light at the end of the tunnel as we see international travel corridors reopening. However, we will continue to track this momentum as new variants arise and we hope the invaluable analyses in our Airline Insights Report help to navigate what’s to come,” said Jeremy Bowen, CEO of Cirium.

Cirium predicts a year of acceleration in 2022

“Cirium’s experts have analysed 2021 data and formulated forecasts for 2022 and beyond. Near the end of 2022, global capacity will return to 2015 levels, as we see a steep increase in more seats returning to the skies.

“In Cirium’s Airline Insights Report, we have included Seven Things to Look for in 2022 to enable the industry to gain insight into these forecasts and use them to anticipate market developments and make well-informed decisions,” Bowen added.

As more passengers steadily return to the skies, this will mean worldwide domestic traffic (measured in passenger numbers) is predicted to be back to pre-pandemic levels by the end of 2022. International passenger traffic is likely to reach two-thirds of 2019 levels.

Cirium projections show that the global passenger fleet in service will increase to 20,700 by the end of 2022—only a few hundred less than at the end of 2019—pre-pandemic.

The slow recovery of business travel seen so far will change in 2022, with predictions from the industry that there will be a 36% surge in business travel year-over-year. According to Cirium data, business events being tracked online are already increasing for next year.

Conversions of passenger jets to freighters will continue to increase and in 2022, with a potential total of 160 passenger jets converted to freighters—surpassing previous conversion figures.

Aircraft values and lease rates took an unprecedented hit in the past 12 months, however Cirium suggests that they’ve reached the bottom as the values and lease rates for many aircraft types have stabilized and a few are improving. Some aircraft types remain on watch next year, including the Airbus A350 and the Boeing 787.

Cirium anticipates that airlines will increasingly rely on partnerships to carry passengers into partner home markets in 2022. This will mean a shift in airlines flying secondary markets post-pandemic and instead see them taking advantage of their airline partners to fly passengers to secondary cities.

As more flights return to the skies, it’s no surprise that CO2 emissions will increase next year—the CO2 emissions from flights in 2021 were 40% less than pre-pandemic. However, airlines are returning more fuel-efficient fleets to service and sustainability has become front and center in aviation, with many looking at fuel burn and how to reach net zero 2050 targets.

“Cirium anticipates the return to normalcy will usher in more focus on sustainable travel practices, including younger, more fuel-efficient aircraft, and the ability to more closely measure the impact of airline travel on global greenhouse gas emissions,” said Bowen.

To read the full Cirium Airline Insights Review 2021, including the seven predictions of 2022 – click here .

The 2021 Airline Insights Report is Cirium’s collection of expert analyses covering a wide range of topics surrounding airlines at the core and the aviation industry that encircles them. The report covers:

  • Top routes flown and airports in 2021
  • The current state of the global passenger traffic, capacity and fleet
  • Sustainability initiatives in the airline industry
  • Airline startups and new routes flown in 2021
  • Average airfares in key markets
  • Spotlights on APAC and Latin America

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye